ArticleBlood cancer journal2025

A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia.

Lena Golick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.